Feokromositoma ameliyatı geçiren hastalarda kan basıncı, kan şekeri ve kreatinin değişiklikleri

Abstract

Objective: To discover the variables that may predict changes in blood pressure and blood sugar levels and to pinpoint the time frame during which such changes occur in patient with pheochromocytoma. Materials and Methods: Consecutive patients undergoing surgery for pheochromocytoma over a 20-month period were included in this ethics review board-approved, prospective cohort study. Blood pressure and sugar levels were serially monitored using a fixed protocol in the perioperative period and subsequently at 3 months after surgery. Changes were compared and assessed for the predictive factors. Results: Fifty patients undergoing surgical procedures were included in the study of whom 32% developed hypotension and 10% developed hypoglycaemias after surgery. All hypotension episodes occurred within 6 hours of surgery. However, while 7 of 8 patients who developed hypoglycaemia manifest in the first 4 h after surgery, one occurred after 12 h. Occurrence of hypotension correlated with preoperative 24-h urinary vanillylmandelic acid levels (P = 0.024). Out of 21 hypertensive patients, 15 had persistent hypertension at 3 months and this was associated with age (P = 0.04) and diabetes mellitus at presentation. Conclusion: 32% of patients receiving pheochromocytoma surgery experienced postoperative hypotension needing inotropic support. Patients who require greater dosages of alpha-blockers or those with higher 24-h urine VMA levels are more prone to experience this. This happens within the first six hours following surgery. Patients who are older or who have had DM for a long time are more likely to suffer chronic HTN following surgery.

Keywords

• Pheochromocytoma
• hypertension
• hypoglycaemia
• creatinine.

Changes in blood pressure, blood sugar and creatinine in patients undergoing pheochromocytoma surgery

Abstract

Objective: To discover the variables that may predict changes in blood pressure and blood sugar levels and to pinpoint the time frame during which such changes occur in patient with pheochromocytoma. Materials and Methodology: Consecutive patients undergoing surgery for pheochromocytoma over a 20-month period were included in this ethics review board-approved, prospective cohort study. Blood pressure and sugar levels were serially monitored using a fixed protocol in the perioperative period and subsequently at 3 months after surgery. Changes were compared and assessed for the predictive factors. Result: Fifty patients undergoing surgical procedures were included in the study of whom 32% developed hypotension and 10% developed hypoglycaemias after surgery. All hypotension episodes occurred within 6 hours of surgery. However, while 7 of 8 patients who developed hypoglycaemia manifest in the first 4 h after surgery, one occurred after 12 h. Occurrence of hypotension correlated with preoperative 24-h urinary vanillylmandelic acid levels (P = 0.024). Out of 21 hypertensive patients, 15 had persistent hypertension at 3 months and this was associated with age (P = 0.04) and diabetes mellitus at presentation. Conclusion: 32% of patients receiving pheochromocytoma surgery experienced postoperative hypotension needing inotropic support. Patients who require greater dosages of alpha-blockers or those with higher 24-h urine VMA levels are more prone to experience this. This happens within the first six hours following surgery. Patients who are older or who have had DM for a long time are more likely to suffer chronic HTN following surgery.

Keywords

• Pheochromocytoma
• hypertension
• hypoglycaemia
• creatinine.

References

1. 1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. The Lancet 2005;366:665–675. https://doi.org/10.1016/s0140-6736(05)67139-5
2. 2. Zelinka T, Eisenhofer G, Pacak K. Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice. Stress 2007;10:195–203. https://doi.org/10.1080/10253890701395896
3. 3. Bravo EL, Tagle R. Pheochromocytoma: stateof-the-art and future prospects. Endocr Rev. 2003;24(4):539-53. https://doi.org/10.1210/er.2002-0013
4. 4. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma--views on current management. Eur J Surg Oncol. 2003;29(6):483- 490. https://doi.org/10.1016/s0748-7983(03)00071-4
5. 5. Kercher KW, Novitsky YW, Park A, Matthews BD, Litwin DE, Heniford BT. Laparoscopic curative resection of pheochromocytomas. Ann Surg. 2005;241(6):919-26; discussion 926-928. https://doi.org/10.1097/01.sla.0000164175.26785.06
6. 6. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 2003;21(9):1703- 7. https://doi.org/10.1097/00004872-200309000-00020
7. 7. Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery 2014;156:1404–1409. https://doi.org/10.1016/j.surg.2014.08.020
8. 8. Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Oden A, Stenstrom G, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. Journal of Internal Medicine. 2005;258:55–66. https://doi.org/10.1111/j.1365-2796.2005.01504.x

9. 9. Pogorzelski R, Toutounchi S, Krajewska E, Fiszer P, Łykowski M, Zapała Ł, Szostek M, Jakuczun W, Pachucki J, Skórski M. The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent European J Urol. 2014;67(4):361-365. https://doi.org/10.5173/ceju.2014.04.art9
10. 10. Spyroglou A, Adolf C, Hahner S, Quinkler M, Ladurner R, Reincke M, Beuschlein F. Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy. Horm Metab Res. 2017;49(3):208-213. https://doi.org/10.1055/s-0042-124189
11. 11. Rao N, Ramachandran R, Tandon N, Singh P, Kumar R. Surgical and Hemodynamic Outcomes in Pheochromocytoma Surgery: A Prospective Cohort Study. Urology. 2016;98:103-106. https://doi.org/10.1016/j.urology.2016.09.004
12. 12. Bénay CE, Tahiri M, Lee L, Theodosopoulos E, Madani A, Feldman LS, Mitmaker EJ. Selective strategy for intensive monitoring after pheochromocytoma resection. Surgery. 2016;159(1):275-282. https://doi.org/10.1016/j.surg.2015.06.045
13. 13. Brunaud L, Boutami M, Nguyen-Thi PL, Finnerty B, Germain A, Weryha G, et al. Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma. Surgery. 2014;156:1410-1417. https://doi.org/10.1016/j.surg.2014.08.022
14. 14. Namekawa T, Utsumi T, Kawamura K, Kamiya N, Imamoto T, Takiguchi T, Hashimoto N, Tanaka T, Naya Y, Suzuki H, Ichikawa T. Clinical predictors of prolonged postresection hypotension after laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2016;159(3):763-770. https://doi.org/10.1016/j.surg.2015.09.016
15. 15. Shao Y, Chen R, Shen ZJ, Teng Y, Huang P,Rui WB, Xie X, Zhou WL. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? J Hypertens. 2011;29(12):2429-32. https://doi.org/10.1097/HJH.0b013e32834d24d9
16. 16. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86(4):1480-1486. https://doi.org/10.1210/jcem.86.4.7392.
17. 17. Yau JS, Li JK, Tam VH, Fung LM, Yeung CK, Chan KW, Lee KM, Lee KF, Cheung WS, Yeung VT, Yuen YP, Kwan WK. Phaeochromocytoma in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(4):252-256. PMID: 20683066
18. 18. Kazic MR, Zivaljevic VR, Milan ZB, Paunovic IR. Perioperative risk factors, morbidity, and outcome of 145 patients during pheochromocytoma resection. Acta Chir Belg. 2011;111(4):223-227. PMID: 21954738
19. 19. Sapienza P, Cavallaro A. Persistent hypertension after removal of adrenal tumours. Eur J Surg. 1999;165(3):187-192. https://doi.org/10.1080/110241599750007027
20. 20. Petrák O, Haluzíková D, Kaválková P, Štrauch B, Rosa J, Holaj R, Brabcová Vránková A, Michalsky D, Haluzík M, Zelinka T, Widimsky J Jr. Changes in energy metabolism in pheochromocytoma. J Clin Endocrinol Metab. 2013;98(4):1651-1658. https://doi.org/10.1210/jc.2012-3625
21. 21. Bosanska L, Petrak O, Zelinka T, Mraz M, Widimsky J Jr, Haluzik M. The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue. Physiol Res. 2009;58(3):319-325. https://doi.org/10.33549/physiolres.931483